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Abstract
Chronic HIV infection leads to the development of cognitive impairments, designated as HIV-associated neurocognitive
disorders (HAND). The secretion of soluble neurotoxic factors by HIV-infected macrophages plays a central role in the
neuronal dysfunction and cell death associated with HAND. One potentially neurotoxic protein secreted by HIV-1 infected
macrophages is cathepsin B. To explore the potential role of cathepsin B in neuronal cell death after HIV infection, we
cultured HIV-1ADA infected human monocyte-derived macrophages (MDM) and assayed them for expression and activity of
cathepsin B and its inhibitors, cystatins B and C. The neurotoxic activity of the secreted cathepsin B was determined by
incubating cells from the neuronal cell line SK-N-SH with MDM conditioned media (MCM) from HIV-1 infected cultures. We
found that HIV-1 infected MDM secreted significantly higher levels of cathepsin B than did uninfected cells. Moreover, the
activity of secreted cathepsin B was significantly increased in HIV-infected MDM at the peak of viral production. Incubation
of neuronal cells with supernatants from HIV-infected MDM resulted in a significant increase in the numbers of apoptotic
neurons, and this increase was reversed by the addition of either the cathepsin B inhibitor CA-074 or a monoclonal antibody
to cathepsin B. In situ proximity ligation assays indicated that the increased neurotoxic activity of the cathepsin B secreted
by HIV-infected MDM resulted from decreased interactions between the enzyme and its inhibitors, cystatins B and C.
Furthermore, preliminary in vivo studies of human post-mortem brain tissue suggested an upregulation of cathepsin B
immunoreactivity in the hippocampus and basal ganglia in individuals with HAND. Our results demonstrate that HIV-1
infection upregulates cathepsin B in macrophages, increases cathepsin B activity, and reduces cystatin-cathepsin
interactions, contributing to neuronal apoptosis. These findings provide new evidence for the role of cathepsin B in
neuronal cell death induced by HIV-infected macrophages.
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Introduction
HIV-1 infects brain mononuclear phagocytes (MP; monocytes,
perivascular macrophages, dendritic cells and microglia) leading to
a chronic viral infection and consequent neurological impair-
ments, designated as HIV-associated neurocognitive disorders
(HAND) [1]. Importantly, the prevalence of HAND remains high
despite the widespread use of combination antiretroviral therapy
(cART), and affects 30–50% of infected individuals [2,3,4]. Viral
invasion of the central nervous system (CNS) occurs as a conse-
quence of blood-derived monocytes entering the brain across the
blood brain barrier (BBB) [5,6,7]. Although HIV-1 penetrates the
CNS soon after viral infection, neurological symptoms occur only
after immune suppression and coincide with the development of
AIDS [8]. What underlies disease is the secretion of soluble viral
and cellular neurotoxins from activated and infected perivascular
macrophages and microglia [9,10]. The secretion of these factors,
together with severe dysregulation of macrophage function, can
lead to neuronal dysfunction and apoptosis [11,12], resulting in
cognitive impairment.
Although cART can restore immune function by suppressing
viral replication and decreasing the inflammatory neurotoxins that
exacerbate the signs and symptoms of HAND [13], it cannot
prevent disease progression [14,15]. This failure may result from
limited drug penetrance into the CNS, viral mutations, and/or
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proteins that could promote neuronal apoptosis, if not properly
regulated, is cathepsin B, a cysteine protease of lysosomal origin
involved in various important cellular processes such as antigen
processing and presentation [18], apoptosis [19], inflammation
and neurodegeneration [20]. Cathepsin B is found in high
abundance in activated macrophages and has been shown to be
involved in programmed cell death [21]. Under normal conditions
cathepsin B is under stringent regulation due to its potential
detrimental effects on cells. However, oxidative stress and soluble
cytokines may promote the release of cathepsin B from lysosomes
and extracellular secretion by MP. Therefore cathepsin B could in
turn contribute to the apoptosis of adjacent cells by promoting
mitochondrial release of cytochrome c [21].
How HIV-1 infection of macrophages affects interactions
between cathepsin B and its inhibitors, cystatins B and C, and
thereby potentially impact neuronal survival was assessed in the
current study. Human monocyte-derived macrophages (MDM)
were cultured and infected with HIV-1ADA for 12 days, and the
expression of intracellular and extracellular cathepsin B, cystatin
B, and cystatin C in uninfected and HIV-1 infected cells was
monitored over time. Our results demonstrate that HIV-1
infection of MDM leads to increased cathepsin B RNA levels,
and increased cathepsin B secretion, activity, and neurotoxicity.
We also show that cathepsin B is released outside of the lysosome
after HIV infection and that its interactions with cystatins B and C
are decreased. Thus, HIV infection alters cathepsin B activity and
secretion by inhibiting interactions between the protease and its
inhibitors. Moreover, preliminary data suggest increased expres-
sion of cathepsin B in the hippocampus and basal ganglia of post-
mortem brain tissue from HIV-infected individuals diagnosed with
HAND, Alzheimer’s disease, and other neuropsychiatric disorders.




Research involving human participants was approved by the
University of Puerto Rico Institutional Review Board (Protocol
0720109). Blood was collected in ACD tubes for isolation of
peripheral blood mononuclear cells (PBMC) after obtaining
a written informed consent. Data was analyzed anonymously.
Isolation and Culture of Primary Macrophages
PBMC were isolated from healthy donors by Ficoll density
gradient separation. Adherent monocytes were grown in RPMI
supplemented with 20% heat-inactivated FBS, 10% heat-inacti-
vated pooled human sera, and 1% Pen/Strep (all from Sigma
Chemical Company, St. Louis, MO) in T25 flasks at a concentra-
tion of 1.5610
6 cells/ml. Half of the medium was changed every
3 days for all cultures. At seven days, adherent cells were .90%
MDM [22].
Infection of Monocyte Derived Macrophages
HIV-1ADA isolate was kindly provided by Dr. Howard
Gendelman (University of Nebraska Medical Center). HIV–
1ADA was originally isolated from peripheral blood mononuclear
cells of an AIDS patient with Kaposi’s sarcoma and propagated
in MDM obtained from HIV-1-seronegative donors after
ultracentrifugation as previously described [23]. Viral prepara-
tions were screened for endotoxin (10 pg/ml) (Associates of
Cape Cod, Woods Hole, Mass.) and Mycoplasma (Gen-Probe
II; Gen-Probe, San Diego, Calif.). Viral titer was determined on
PHA-blasts as 10
3 TCID50/ml.
After 7 days in culture, MDM were infected with HIV-1ADA at
a multiplicity of infection (MOI) of 0.1 or with serum-free media
only (uninfected controls) [24]. After overnight incubation, virus
was thoroughly washed away and fresh medium was added.
Infected MDM were maintained in culture for up to 12 days.
Culture supernatants were collected at different days post infection
(dpi) depending on the analysis, centrifuged, and stored at 280uC.
Infection efficiency was determined in MDM supernatants at 3, 5,
7, 9 and 12 dpi by HIVp24 antigen ELISA, following the
manufacturer’s instructions (Express BioTech, Maryland, USA).
Protein expression, function, and apoptotic activity were de-
termined in supernatants collected at 3, 6, 9 and 12 dpi. Cells were
harvested at the same time points for quantitative intracellular
messenger RNA analysis.
Quantitative Real Time PCR
For quantitative real time PCR experiments, cell pellets were
collected at 3, 7, and 12 days post-infection from 8 MDM cultures.
RNA was isolated from the pellets using the Qiagen RNeasy
Protect kit and quantified using the Nanodrop system. RNA
integrity was assessed with the RNA Nanoassay in an Agilent 2100
Bioanalyzer. RNA samples were stored at 280uC for subsequent
Real Time PCR analysis. RNA was analyzed for differential
expression of cathepsin B, cystatin B, and cystatin C, target genes
using GAPH as an internal reference gene, using the Quantitect
SYBR Green RT-PCR kit (Qiagen). All primers were tested for
their specificity as well as for the absence of primer-dimer
formation by PCR, followed by agarose gel electrophoresis. Real
time RT-PCR reactions were conducted at a final volume of
25 mL using 20 ng of total RNA and 40 cycles of amplification, as
recommended by the Qiagen Handbook, in an ABI StepOne Plus
cycler. The fold change of detected amplicons was calculated by
comparing the average threshold cycles (Ct) of the reference gene
to that of the target genes by the delta delta Ct method [25,26].
Preparation of Cell Lysates
Cells were washed in cold PBS and incubated on ice for 30 min
with cell lysis buffer (5 mM Tris-HCL buffer at pH 8.0, 0.1%
Triton X-100, and protease inhibitor solution, (Sigma), (100 mL/
1million cells; Sigma) [cocktail protease inhibitor ratio: 5 mL/
100 mL lysis buffer]). Lysates were cleared by centrifugation for
10 min at 1,500 rpm at 4uC, and stored at 280uC for future
analyses. Protein concentration was determined using the DC
protein assay (BioRad, California, USA) following the manufac-
turer’s instructions.
Western Blot Analysis
MDM cell lysates containing 30 mg of protein as determined by
DC protein assay (BioRad) were subjected to high-speed
centrifugation overnight at low temperature to obtain protein
pellets. Samples were rehydrated in 12 ml of sample buffer (475 mL
of Laemmli sample buffer and 25 mLo fb-mercaptoethanol (BME,
BioRad) and heated at 70uC for 10 minutes. Samples diluted in
sample buffer were loaded onto 4%220% Tris-HCL 15-well
Ready Gels (BioRad), together with a molecular weight marker
and positive controls for cystatins B and C (U87 cell lysates) and
cathepsin B (isolated human protein from liver, Biovision,
California, USA). Gels were run with NuPAGE Protocol at 200
V for 40 min. After electrophoresis, gels were rinsed with PBS and
then transferred to a nitrocellulose membrane using the semi-dry
transfer method on a transblot apparatus (BioRad) for 30 min (per
gel) at 25 V. After transferring, membranes were blocked with 3%
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temperature with shaking. Membranes were probed with rabbit
anti-human cathepsin B (1:500) (Chemicon, Massachusetts, USA);
mouse anti-human cystatin C (1:500); mouse anti-human cystatin
B (1:1000) (Sigma, Missouri, USA), followed by secondary anti-
rabbit Ig G- conjugated with Horseradish Peroxidase (HRP)
(Sigma) or anti-mouse IgG-HRP Sigma), respectively. All incuba-
tions with primary antibodies were done overnight at 4uC, while
all incubations with secondary antibodies were done for 1hour at
room temperature. Following incubations with primary and
secondary antibodies, membranes were washed with TTBS.
Chemiluminescence (Super Signal West Femto Detection Kit,
Pierce, Massachussets, USA) was used for signal detection. The
density of protein bands was determined using the Versa Doc
System with Quantity One Software (BioRad) and normalized
against the levels of b-tubulin detected with monoclonal mouse
anti-b-tubulin (Sigma) as indicated above.
Cystatins and Cathepsin B ELISAs
Sandwich ELISA (R & D Systems, Minnesota, USA) was used
for the quantification of expression of secreted cathepsin B in
MDM (1:100 dilution) following the manufacturer’s instructions
and measured in nanograms per milliliter (ng/mL). Extracellular
cystatin C was assayed by human cystatin C ELISA (BioVendor,
North Carolina, USA) following the manufacturer’s instructions.
Briefly, 100 ml of each sample were incubated in a plate pre-
coated with polyclonal anti-human cystatin C specific antibody for
30 min. After incubation, the plate was washed and 100 mlo f
conjugate solution was added to each well and incubated for
30 min. Substrate solution was then added and incubated for
10 min in the dark. The expression of cystatin B was measured
with an ELISA (USCN Life Science Inc, China) according to the
manufacturer’s instructions. Samples from 5 different donors were
tested in duplicates as recommended by the manufacturer. Optical
density of all ELISAs was determined by reading absorbance at
450 nm in a Dynex MRX Revelation Microplate Reader
(Chantilly, VA).
Cathepsin B Activity Assay
The bioactivity of secreted cathepsin B was detected using the
cathepsin B Activity Assay Kit (Bio Vision, California). This kit is
a fluorescence-based assay that utilizes the preferred cathepsin B
substrate sequence Arginine-Arginine (RR) labeled with amino-4-
trifluoromethyl coumarin (AFC). Samples containing active
cathepsin-B cleave the synthetic substrate RR-AFC to release free
AFC. The released AFC can easily be quantified by fluorescence.
This assay has been used extensively by other researchers to
determine active cathepsin B levels [27]. MDM supernatants
collected from cell cultures at 3, 6, 9, and 12 days post infection
(dpi) were assayed in duplicate following the manufacturer’s
instructions. Signal was detected using the VersaFluor TM
Fluorometer (BioRad) fluorescence plate reader equipped with
a 400-nm excitation filter and a 505-nm emission filter.
The intracellular activity of cathepsin B was determined using
the CV-cathepsin B Detection kit (BIOMOL International LP)
according to the manufacturer’s protocol. Briefly, PBMCs were
cultured in sterile 4-well slide chambers at 2610
6 cells per well and
allowed to differentiate into MDM for 7 days. At day 7, cultures
were inoculated with HIV-1ADA or with serum-free media
(uninfected controls) as described above, and kept in culture for
12 dpi. Half of the culture medium was changed every 3 days. At
day 12 dpi, arginine-conjugated cresyl violet (CV-RR2), was added
to the culture media and incubated for 60 min at 37uCi n5 %
CO2. The attached Arg–Arg group is a preferred substrate for
cathepsin B cleavage, and in presence of cathepsin B is detached
from CV, which can be detected by its fluorescence when
unconjugated. Fluorescence intensity of unconjugated CV was
determined at 550 nm for excitation and 610 nm for emission of
five fields per well per experimental group. Samples were
visualized with a confocal microscope (LSM5 Pascal; Carl Zeiss,
Jena, Germany) within 1 hour.
Neuroblastoma SK-N-SH Cell Cultures
SK-N-SH (HTB-11) cells (human neuroblastoma line, ATCC),
were grown and plated on 6-well plates at a density of 7610
5 cells
per well and maintained in Eagle’s MEM (EMEM) supplemented
with 10% fetal bovine serum (FBS; Sigma), 1% sodium pyruvate
(Sigma) and 1% non-essential amino acids (Sigma) and incubated
for 3–5 days at 37uC, 5% CO2 until 70–80% confluence.
Determination of Cathepsin B Neurotoxic Potential
Confluent SK-N-SH cells were washed twice with PBS and
incubated for 24 h with fresh MDM conditioned medium (MCM)
from uninfected or HIV-infected MDM cultures derived from four
different donors at 1:4 dilution in plain EMEM. MCM was added
with or without a specific cathepsin B inhibitor CA-074 (Sigma) at
a concentration of 50 mM. The cathepsin B inhibitor CA074 (L-3-
trans-propylcarbamoyloxirane-2-carbonyl)-Lisoleucyl-L-proline) is
a very rapid inactivator of cathepsin B with barely detectable
action on cathepsins H, L, and S or m-calpain [28]. For
experiments examining apoptosis by TUNEL assay and confocal
microscopy, SK-N-SH cells were grown and plated on 4-well
chamber slides at a density of 1610
5 cells per well in the culture
media described above. Cells were incubated for 3–5 days at 37uC,
5% CO2 until 70–80% confluence. MCM was added to 75–80%
confluent SK-N-SH cultures, and incubated at 37uC, 5% CO2 for
24 hours. In addition to CA-074, a monoclonal mouse anti-
cathepsin B antibody at 1:500 (Sigma), representing 50x the
concentration of secreted cathepsin B, was used to inhibit the
enzyme based on the manufacturer’s protocols. The next day,
neurons were washed with PBS and fixed using 4% para-
formaldehyde. Fixed neurons were incubated for 10 minutes in
3% hydrogen peroxide in methanol to quench auto-fluorescence,
and were permeabilized in 0.1%Triton X-100 in 0.1% sodium
citrate for 10 minutes on ice. In situ TUNEL labeling (ROCHEH)
was performed incubating neurons in TUNEL reaction mix
(terminal transferase enzyme solution to labeled nucleotides
solution ratio 1:10) for 1 hour at 37uC on a humidity chamber
in dark environment. Cells were washed 3 times in PBS, and
DAPI, diluted in anti-fade mounting media (VectashieldH) was
added to all slides at a final concentration of 2 ng/mL. The
negative control consisted of cell incubated in labeling solution
without enzyme under the same conditions. The positive control
was obtained by incubating fixed and permeabilized cells in 30 U/
mL recombinant DNaseI for 10 minutes at room temperature to
induce DNA strand breaks, and then labeling them by TUNEL
reaction. Confocal microscopy was performed with a Zeiss
confocal microscope Axiovert 200 M with a LSM 510 under an
excitation wavelength of 488 nm, 206magnification.
DuoLink in situ Proximity Ligation Assay (PLA) for Protein-
protein Interactions
The Duolink II proximity ligation assay kit, composed of anti-
rabbit PLA probe plus, anti-mouse PLA probe minus, and
detection kit Orange (ex 554, em576) was purchased from Olink
Bioscience (Uppsala, Sweden). MDM were cultured in 4 well
Premanox chamber slides (Fisher) and inoculated with HIV-1ADA
MDM-HIV Secreted Cathepsin B and Neuronal Death
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36571or serum free media (uninfected controls) as described above. At 3,
6 and 12 dpi cells were fixed in 4% paraformaldehyde and
permeabilized using 0.1% Triton-X100/BSA and stored in 4%
paraformaldehyde solution for future experiments.
Fixed cells were washed with PBS to remove fixing solution and
then blocked in a pre-heated humidity chamber with Duolink II
Blocking Solution for 30 min at 37uC. Primary antibody mixtures
were prepared by diluting antibodies in Duolink II Antibody
Diluent at optimal dilutions: cathepsin B (1:250, Chemicon)
cystatin B (1:1,000, R and D) and cystatin C (1:250, R and D) and
incubated overnight at 4uC with gentle shaking. All Duolink II
reagents were diluted according to the manufacturer’s instructions.
Samples were air dried and mounted with Duolink II Mounting
Media containing DAPI nuclear stain. Detection of the interaction
signals was carried out by red fluorescence imaging performed on
a Zeiss LSM 5 confocal laser-scanning microscope, equipped with
a6 3 6objective and with an Argon Laser, a 543 He-Ne laser (red),
405 (blue) Laser and a Halogen Lamp.
Immunofluorescence Staining
To determine the presence of individual proteins in the samples
stained for in situ PLA, cells fixed in 4% paraformaldehyde were
incubated with rabbit-anti-cathepsin B (1:500, Chemicon); mouse-
anti-cystatin B (1:2,000, R and D) and mouse-anti-cystatin C
(1:500, R and D) and incubated in blocking buffer (3% BSA)
overnight at 4uC followed by Alexa-conjugated secondary
antibodies anti-rabbit Ig G-543 (1:500) or anti-mouse IgG-488
(1:500), Invitrogen). Cells were washed 3–5 times for 10 min with
PBS between incubations. Cell preps were allowed to air dry,
mounted with Vectashield mounting media (Vector Labs) contain-
ing DAPI stain and visualized in a Zeiss LSM 5 confocal laser-
scanning microscope as described above.
Immunohistochemistry of Frozen Human Post-mortem
Brain Tissues
Brain tissue samples snap-frozen without cryopreservatives were
obtained from the National NeuroAIDS Tissue Consortium, from
7 individuals represented under the following categories: three
uninfected, one HIV-infected without cognitive impairment, one
HIV-infected with HAD, one HIV-infected with minor cognitive
and motor dysfunction (MCMD), one HIV-infected with HIV
encephalitis (HIVE) and Alzheimer’s disease, and one HIV-
infected with neuropsychological impairment due to other cause
(Table 1). For each individual, samples were obtained from three
brain regions: basal ganglia, frontal lobe and hippocampus.
Samples were fixed in Zambonie solution (2% paraformaldehyde
and 0.2% picric acid) for 24 hours at 4uC and then washed with
anti-freeze solution (30% Ethylene Glycol, 15% sucrose, 0.1%
PBS) and sectioned into 20 mm samples with a microtome using
dry ice and 30% sucrose solution. Sections were stored in anti-
freeze solution at 4uC, and the original samples were stored in
anti-freeze solution at 220uC.
Sections were washed twice with 16 PBS for 5 minutes,
permeabilized with 0.1% Triton X-100 and then blocked using
10% BSA in PBS for 1 hour at room temperature (RT). The
following primary antibodies were diluted in blocking buffer and
added to the tissue for 12 hours at 4uC: monoclonal mouse anti-
cystatin B (R&D systems, 1:200); polyclonal rabbit anti-human
Ionized calcium binding adaptor molecule 1 (Iba1, a specific
marker for microglia and macrophages) (Wako, 1:250); mono-
clonal mouse anti-human cathepsin B (Sigma, 1:100). Tissues were
washed in PBS 3 times for 5 minutes at RT and. The following
Alexa fluor-conjugated secondary antibodies were added: 488 goat
anti-mouse and 546 goat anti-rabbit. Secondary antibodies were
diluted to 1:200 in blocking buffer and added for 1 hour in the
dark at RT. Tissues were washed 3 times in PBS for 5 minutes in
dark environment. Tissue preps were allowed to dry and mounted
using Vectashield (VectorLabsH) as anti-fade with or without
DAPI nuclear stain (1:500). Fluorescence was detected using
a Zeiss LSM 5 confocal laser-scanning microscope equipped with
an argon laser, a 543 He-Ne laser (red), 405 (blue) laser and
a halogen lamp, at 636 magnification. For every tissue, two
control tissue slides were prepared: one unstained and one stained
with secondary antibodies alone. Detector gains in the Pascal
Software were manipulated using both types of control tissue preps
to minimize unspecific staining and background. Once each color
gain was set using the control slides, each slide was examined at
least twice and a minimum of two pictures from each sample were
taken under the same parameters.
Analysis
Prior to confirmatory statistical analysis, distributional assump-
tions were tested using Shapiro-Wilk test of normality. Based on
the results of these distributional tests, the assumption of normality
could not be supported. Therefore, non-parametric tests statistics
were used to address the questions in this research project.
Descriptive statistics were calculated for each laboratory measure
(e.g. measures of apoptosis), stratified by HIV infection, presence
of inhibitor and days post infection, using median and interquartile
range (25
th and 75
th percentile of the distribution). Wilcoxon rank
sums were used to test the hypotheses of: 1) no difference between
HIV infected and uninfected cultures prior to the introduction of
inhibitor; 2) no difference between HIV infected cultures before
and after introduction of inhibitor; and 3) no difference between
HIV uninfected without inhibitor and HIV infected with inhibitor.
Statistical significance was considered at p,0.05 for all
comparisons. All statistics were performed using SAS, version
9.2 (The SAS Institute, Cary, NC).
Results
Intracellular Expression of Cathepsin B and its Inhibitors
in HIV-1 Infected MDM
It is well known that HIV-1 infection alters host cell biology at
both the transcriptional and post-transcriptional level [29,30].
Previous proteomic studies from our laboratories identified
cathepsin B and cystatin B as differentially expressed in HIV-
infected macrophages [31]. To determine if HIV-1 has an effect
on the expression of genes for cathepsin B and its inhibitors,
cystatins B and C, we performed real time PCR of HIV-infected
and uninfected MDM cultures from 8 different donors. Samples
were analyzed to determine changes in mRNA levels at 3, 7 and
12 dpi. Productive infection was determined in cell supernatants as
an increase in HIV p24 protein over the time in culture (data not
shown). There was a significant increase in cathepsin B mRNA at
day 12 compared to day 3 (p=0.026) and day 7 post-infection
(p=0.038) (Figure 1). Levels of mRNA for cystatin B and cystatin
C did not differ between HIV-1-infected and uninfected samples.
The effect of HIV-1 infection on MDM expression of cathepsin
B and its inhibitors, cystatin B and cystatin C, was assessed by
Western blot and densitometry analysis. Protein expression was
analyzed from 4 donors at 6, 9 and 12 dpi. The relative abundance
of intracellular cathepsin B was similar in HIV-1 infected and
uninfected control cells (Supplement 1). During peak virus
production, cystatin B expression was significantly higher in
HIV-infected MDM than in uninfected cells (p=0.037, Figure
S1). We analyzed intracellular expression of cystatin C in MDM
MDM-HIV Secreted Cathepsin B and Neuronal Death
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uninfected MDM (Figure S1).
Cathepsin B is Secreted from MDM at Higher Levels than
Cystatin C but is not Higher than Cystatin B
Under normal conditions, cathepsin B is located inside
lysosomes, but oxidative stress induced by HIV-1 infection could
stimulate the release of cathepsin B from this cellular compart-
ment. We hypothesized that HIV-1 infection induces the release of
cathepsin B from lysosomes to the cytoplasm and the extracellular
medium. Therefore, we compared levels of cathepsin B secreted
by HIV-infected MDM obtained from 7 different donors with
productive infection (as demonstrated by increased levels of HIV-1
p24 antigen over time) to those secreted by MDM obtained from
uninfected controls (data not shown). Both uninfected and HIV-
infected MDM secreted cathepsin B into the culture medium
(range: 125 ng/ml to 590 ng/ml) (Figure 2). However, HIV-
infected MDM secreted significantly higher levels of cathepsin B
than did uninfected MDM at 12 days post-infection, when virus
production and cathepsin B mRNA levels peak (p,0.05). These
results suggest that HIV-1 infection induces the synthesis and
rapid secretion of cathepsin B into the MDM supernatants.
We next asked if HIV-1 infection could modulate the expression
of the cathepsin B inhibitor cystatin C, since the latter is the major
extracellular inhibitor of cathepsin B. Expression of cystatin C and
the ratio between secreted cathepsin B and cystatin C determines
the amount of potentially active cathepsin B in the extracellular
medium. We found that the levels of cystatin B and cystatin C in
the culture fluids were similar in HIV-1 infected and uninfected
MDM throughout the infection (Figure 2B and 2C). We then
compared the ratio of secreted cathepsin B to cystatin B and
Cystatin C to determine if there was an imbalance between the
two proteins that could lead to higher cathepsin B activity. At 12
dpi, cathepsin B was expressed at 2 to 4.5-fold higher levels than
cystatin C (p,0.01; Figure 2D). There was a significantly greater
increase in cathepsin B relative to cystatin C in HIV-infected
versus uninfected MDM (p=0.030; Figure 2D). These data
confirmed that HIV-1 infection induces an imbalance between
secreted cathepsin B and cystatin C levels. In contrast, the ratio of
cathepsin B to cystatin B revealed that cathepsin B is expressed at
significantly lower levels than cystatin B (Figure 2D).
HIV-1 Infection Increases Secreted Cathepsin B Activity
in MDM
To determine the activity of intracellular cathepsin B in HIV-
infected and uninfected samples, we isolated and cultured MDM
from four additional female donors for in vitro infections with
HIV-ADA. Cell lysates and culture fluids were collected at 3, 6, 9
and 12 dpi. There was a significant increase in HIV p24 antigen
during the time after 6 days post-infection (data not shown).
Cathepsin B intracellular activity in both HIV-infected and control
uninfected samples remained unchanged throughout the infection
(Figure 3). To determine the extracellular activity of cathepsin B,
supernatants from MDM cultures were assayed for cathepsin B
activity using a fluorescently-labeled cathepsin B substrate.
Fluorescence intensity reflected cathepsin B activity, which was
expressed as the percentage of a negative control (MDM culture
media). Both HIV-infected and uninfected cultures secreted active
cathepsin B (Figure 3). However, there was a significant increase in
cathepsin B activity in HIV-infected MDM relative to uninfected
MDM over time in culture (p=0.002) with a mean estimated
increase of 9.2562.61 RFU/day. Cathepsin B activity was
Table 1. Post-mortem brain tissues received from the National NeuroAIDS Tissue Consortium.
CASE ID Path Status Neurocognitive Status Age at Death
7102197786 no HIVE
1 HIV-, no neurocognitive assessment 44
7101267166 no HIVE HIV-, no neurocognitive assessment 51
7101808383 no HIVE HIV-, no neurocognitive assessment 51
CE106 no HIVE Neuropsychological impairment due to other cause: learning disability,
probable psychiatric comorbidity (bipolar, schizophrenia)
29




4028 no HIVE Possible HAD
2 46
5007 HIVE, Alzheimer’s Possible MCMD
3 37
1)HIVE: HIV encephalitis.
2)HAD: HIV associated dementia.
3)MCMD: Minor cognitive motor disorder.
doi:10.1371/journal.pone.0036571.t001
Figure 1. Increased cathepsin B mRNA after HIV infection. MDM
from 8 different donors were inoculated with HIV-1ADA or with serum-
free media (uninfected controls) for 12 days and cell pellets collected at
3, 7, and 12 days post-infection. Changes in mRNA levels are shown as
Fold change =2
DDCt =2
(D Ct control – D Ct experimental) for cathepsin B
(white), cystatin B (grey), and cystatin C (black). The mRNA levels of
cystatins B and C remained similar after HIV infection. A significant
increase in mRNA expression was found for cathepsin B in HIV infected
MDM at 12 days compared to 3 (*p=0.038, B) and 7 dpi (*p=0.028).
doi:10.1371/journal.pone.0036571.g001
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and p=0.043, respectively, Figure 3). A trend of increased
cathepsin B activity was observed at days 6 and 9 post-infection.
These results indicate that MDM normally secrete active cathepsin
B, and that cathepsin B secretion is increased at 12 days post-
infection, when viral production peaks. Hence, these results
provide preliminary evidence for a correlation between viral
production and cathepsin B activity, although further validation of
this correlation with a larger number of donors will be required.
MDM-secreted Cathepsin B Contributes to Neuronal
Apoptosis Induced by HIV-1 Infection
To determine the role in neuronal injury of HIV-induced
cathepsin B secretion by MDM, differentiated neuronal cells from
the neuroblastoma cell line SK-N-SH were incubated with MCM
from four uninfected and HIV-infected cultures collected at 6 and
12 dpi. For this experiment, we determined the optimal
concentration of MCM by comparing undiluted and 1:2 or 1:4
diluted MCM. The 1:4 dilution was chosen for all subsequent
experiments (data not shown). Neuronal apoptosis was determined
using TUNEL labeling and the images were analyzed by confocal
microscopy (Figure 4A). A significant increase in percentage of
apoptotic neurons was observed after exposure to MCM obtained
at 12 days post-infection with HIV-1 (p,0.05) compared to
neurons treated with uninfected MCM. The apoptosis induced by
MCM obtained at 12 dpi was significantly decreased (p,0.01) by
Figure 2. Effect of HIV infection on cathepsin B secretion in
macrophages. Cell supernatants (n=4) from HIVADA-infected (solid
bars) and uninfected (open bars) macrophage cultures were collected,
centrifuged, and tested for cathepsin B, cystatin B and cystatin C
expression by antigen capture ELISA. (A) MDM secreted high levels of
cathepsin B at all time points assayed. There was an increase in
cathepsin B expression in the HIV-infected samples as compared with
uninfected controls at 12 dpi (*p,0.05; A). HIV-infected and uninfected
macrophages showed no differences in secretion of cystatin C or B (B
and C). The ratio of cathepsin B to cystatin B and cathepsin B to cystatin
C were calculated over time in culture (D). Cystatin B was present at
higher concentrations than cathepsin B at all time points assayed, as
indicated by the ratio of cathepsin B to cystatin B lower than 1.
However, an increased cathepsin B to cystatin C ratio was observed in
both HIV-infected and uninfected macrophages at all time points. At 12
dpi the ratio of cathepsin B to cystatin C in HIV-infected cells was higher
in HIV-infected than uninfected cells (*p,0.05, D).
doi:10.1371/journal.pone.0036571.g002
Figure 3. Secreted cathepsin B is more active in HIV-infected
macrophages than in uninfected controls. Protein activity was
measured by adding a synthetic peptide specific for cathepsin B
conjugated to a red fluorogenic compound (RR2-AFC) and read in
a fluorometer at 400 nm excitation and 505 nm emission filters. Culture
fluids from HIV-infected macrophages showed a significant increase in
the activity of secreted cathepsin B at 3 and 12 days post infection
(*p#0.05). Results for cathepsin B activity are expressed as percentages
of control (media only). Increased cathepsin B activity over the days
after HIV infection (mean estimate increase/day 9.25 (SE 2.61),
p=0.002). The specificity of the assay is shown by the abrogation of
any active cathepsin B after the addition of an inhibitor.
doi:10.1371/journal.pone.0036571.g003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36571Figure 4. Cathepsin B contributes to neuronal apoptosis caused by HIV-infected MDM. Apoptosis was measured using terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay at 6 and 12 days post-infection as shown by green fluorescence in neurons
stained with DAPI (blue) (Panel A). These results in panel A are representative of four experiments. The SK-N-SH cells exposed to MCM from
uninfected MDM (1–2) with the cathepsin B antibody (3–4) do not show apoptosis. Neuronal apoptosis increased after exposure to HIV infected MCM
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medium. A similar decrease in apoptotic activity was seen when
the MCM was pre-treated with cathepsin B antibody (Figure 4B)
(p,0.01). Results are represented as mean +/2 SD of four
different experiments.
HIV-1 Infection Induces the Release of Cathepsin B from
Lysosomes
Cathepsin B is a protease of lysosomal origin [32] whose
secretion is preceded by translocation from the lysosome to the
cytoplasm. We hypothesized that HIV-1 infection induces the
release of cathepsin B from the lysosome to the cytosol and
subsequently to the extracellular space. To visualize cathepsin B
within lysosomes before and after HIV-1 infection, we performed
double-immunofluorescence studies of cathepsin B and the
lysosomal-associated membrane protein 2 (LAMP2) by in situ
PLA co-localization assay (Figure 5). Cathepsin B localized to
lysosomes is shown as red fluorescent signal, which that is
detectable only if the two cathepsin B and LAMP2 are present in
close proximity. The results showed little or no red fluorescence in
HIV-infected samples (Figure 5D, E and F, bottom panel)
compared to uninfected controls (Figure 5A, B and C, top panel)
at all time points assayed. Thus, cathepsin B disappeared from
lysosomes after HIV-1 infection. We confirmed that the absence of
red fluorescence was due to absence of cathepsin B from lysosomes
by immunofluorescent staining of cathepsin B and LAMP2 with
Alexa-conjugated secondary antibodies (Figure 5, right panel).
Both LAMP2 (green) and cathepsin B (red) were expressed at high
levels in uninfected controls (Figure 5G, H and I) and HIV-
infected samples (Figure 5J, K and L). The merged image of
LAMP2 and cathepsin B staining shows little or no co-localization
of the two proteins in the HIV-infected samples (Figure 5L). This
data indicates decreased levels of cathepsin B within lysosomes in
HIV-infected samples, suggesting that cathepsin B is released to
other compartments.
HIV-1 Inhibits the Interactions between Cathepsin B and
its Inhibitors
To further understand the role of cathepsin B inhibitors in
cathepsin B secretion and neurotoxicity after HIV-1 infection, we
analyzed the protein-protein interactions between cathepsin B and
cystatins B and C by in situ PLA (Figures 6 and 7). The presence of
individual proteins was confirmed by immunofluorescent staining
(Figures 6 and 7, left panel). As expected, results from uninfected
controls showed that cathepsin B interacts with both cystatin B
(Figure 6, top panel) and cystatin C (Figure 7, top panels) at all
time points assayed. However, little or no interaction between
cathepsin B and its inhibitors was seen in HIV-1-infected samples
(Figure 6 and 7 bottom panels). These results provide strong
evidence that HIV-1 infection not only induces the secretion of
bioactive cathepsin B, but also inhibits and the protease’s
interactions with its inhibitors. This dysfunction in protease/
inhibitor interactions might facilitate the secretion of bioactive
cathepsin B.
Cathepsin B and Cystatin B Expression in Brains of HIV-
infected Individuals with Cognitive Impairment
We did a preliminary analysis of cathepsin B and cystatin B
expression in samples of post-mortem brain tissue obtained from
three uninfected and four HIV-infected individuals. Cathepsin B
protein was undetectable in hippocampus of HIV-negative
individuals (Figure 8A) and the HIV-positive individual with
normal cognition (Figure 8B). In contrast, low levels of cathepsin B
were seen in the hippocampus of an HIV-1 positive individual
with HIV-associated dementia (HAD) (Figure 8C), and higher
levels in an individual with mild cognitive motor disorder
(MCMD) (Figure 8D). We should emphasize that the latter
individual had two additional neurological complications: HIV
encephalitis (HIVE) and Alzheimer’s disease. In addition, low
levels of cathepsin B staining were seen in the hippocampus of an
individual with a history of neuropsychological impairment due to
schizophrenia and bipolar disorder (Figure 8E). Interestingly,
however, cystatin B as well as cathepsin B immunoreactivity was
elevated in the hippocampus from the HIV-1 positive individual
with MCMD (Figure 8I). Double-staining of tissue with an
antibody to the macrophage marker Iba-1 did not significant
overlap with cathepsin B or cystatin B staining, suggesting that
latter proteins are localized either extracellularly or in other cell
populations. Future experiments will be conducted with antibodies
against neurons, astrocytes, and vascular endothelial and smooth
muscle cells to further explore the identities of the cell populations
expressing these two enzymes in HIV-infected brains. Hippocam-
pus samples from the same patients stained only with secondary
antibodies and DAPI were used as negative controls and did not
show immunoreactivity (Figures 8K–O).
Results similar to those seen for hippocampus were obtained in
the basal ganglia (Figure 9). In contrast, no changes in cathepsin B
or cystatin B immunoreactivity were observed in frontal lobe tissue
samples from HIV-infected individuals relative to controls (data
not shown).
The number of post-mortem brain samples that could be
obtained for this analysis were small, and the tissue was not
optimally fixed and preserved for immunocytochemistry. Thus,
further study of cathepsin B and cystatin B expression in vivo will be
necessary. Nonetheless, these results suggest that cathepsin B is
upregulated in the brains of HIV-infected individuals with
cognitive impairment.
Discussion
Infiltrating macrophages and resident microglia are the
principal producers of HIV-1 in the CNS, and the major
contributors to viral neuropathogenesis [33]. Proteomic analyses
of HIV-infected macrophages revealed that HIV-1 infection
induces profound alterations in the normal physiology of
macrophages, which could contribute to neuronal dysfunction
[31]. These changes include not only the production of
neurotoxins, but also the dysregulation of normal cellular pro-
cesses. We used macrophages differentiated from blood monocytes
from healthy donors to explore cellular mechanisms of neuronal
apoptosis in the brain after HIV-infection. Our study sought to
(5–6) from later times post- infection. Inhibition of cathepsin B with the specific inhibitor CA-074 decreased the neuronal apoptosis in each of the
time points (7–8). Pretreatment of medium with a monoclonal antibody against cathepsin B at 1:500 dilution also decreased neuronal apoptosis (9–
10). Quantitative analysis of staining ratio of apoptotic (green )/non-apoptotic (blue) nuclei using Image-based Tool for Counting Nuclei (ITNC) from
Image J software (NIH) revealed a significant increment in percentage of apoptotic neurons at 12 dpi (p,0.05) compared to neurons treated with
uninfected macrophage conditioned media. However, inhibition of cathepsin B by CA-074 decreased significantly the percentage of apoptotic
neurons at 12 dpi (p,0.01) compared with neurons treated with HIV-infected media. MCM supernatant pre-treated with cathepsin B antibody
reverted the percentage of apoptotic neurons at 12 dpi (p,0.01). Results in panel B represent the mean +/2 SD of four biological replicates.
doi:10.1371/journal.pone.0036571.g004
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between cathepsin B and its inhibitors in macrophages. In the
present study, we found that HIV-1 infection modulates the
expression, secretion and activity of cathepsin B and of its natural
inhibitors, cystatins B and C. We also found that secreted bioactive
cathepsin B contributes to neuronal apoptosis, which can be
reversed by the addition of a specific cathepsin B inhibitor or an
antibody to cathepsin B. This data suggested a dysregulation of
cathepsin B compartmentalization and inhibition systems. Our
results demonstrated that cathepsin B disappears from lysosomes
after HIV-1 infection, suggesting its release from the organelle.
This phenomenon occurred in parallel with the disappearance of
the interactions between cathepsin B and both its inhibitors that
were seen in uninfected control cells. To our knowledge, this is the
first study that links macrophage-secreted cathepsin B with the
neuronal apoptosis associated with HIV-1 infection.
Many studies have consistently linked the presence of infected
and highly activated MP with the onset of early signs of neuronal
injury [34]. These cells are important sources of inflammatory
molecules and neurotoxic products such as TNF-a [35], IL-1b and
IL-6 [35] NO [36], glutamate [37], platelet activating factor [38],
quinolonic acid [39,40], arachidonic acid [41], and viral proteins
(e.g., gp120 and Tat). In many cases, secretion of toxic products by
macrophages occurs as a consequence of profound physiological
alterations caused by HIV-1, [22,42,43,44,45] and in turn alters
altering the cells’ phenotype and ultimately their protective
functions.
Proteomic analyses have enabled the identification of hundreds
of proteins that are differentially or uniquely expressed in HIV-1
infected cells compared to uninfected cells [31]. Cathepsin B and
other proteins belonging to the same papain-like cysteine protease
family, as well as their inhibitors have been identified in HIV
infected macrophages by several research groups [43,46,47,48].
To determine whether cathepsin B might play a role in the
neuronal injury induced by HIV, we first studied the effect of
HIV-1 infection on gene and protein expression. We found
increased transcription of cathepsin B in HIV- infected MDM
after 12 dpi, when HIV replication peaked. However, intracellular
cathepsin B expression remained constant throughout infection in
cultured macrophages, suggesting increased secretion of the
enzyme. We confirmed that HIV-infected macrophages secreted
highly toxic levels of cathepsin B (250 ng/ml; 10 mM; Figure 3B)
compared to uninfected cells. These results are consistent with
other studies using microglia stimulated with chromogranin A,
Figure 5. Cathepsin B is released from lysosomes in HIV-infected MDM. To analyze the lysosomal localization of cathepsin B, cathepsin B
and LAMP2 immunoreactivity were assessed by in situ PLA (Duolink) in uninfected and HIV-infected MDM 3, 6 and 12 dpi. Cathepsin B colocalizes
with LAMP2 in uninfected MDM (A, B and C; top panels). However, little colocalization is seen in HIV infected MDM (D, E and F; bottom panels). The
presence of individual proteins was determined by immunofluorescence staining (G, H, I, J, K and L). As seen in the right panels both, cathepsin B
(red) and LAMP2 (green) are expressed in uninfected (G, H, and I) and HIV-infected (J, K, L) cells. The results presented in this figure are representative
of 3 experiments.
doi:10.1371/journal.pone.0036571.g005
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significant neuronal apoptosis [19]. Although HIV-1 infection did
not affect intracellular cathepsin B levels per se, it increased the
enzyme’s secretion and activity in HIV-infected MDM relative to
uninfected control cells at 3 and 12 dpi. However, we also found
unexpectedly high levels of secreted cathepsin B in uninfected
cells, which suggests that these cells could be secreting cathepsin B
mostly in its precursor forms: i.e., as part of normal cathepsin B
trafficking mechanisms (as reviewed by Brix and collaborators
[32]). It remains to be determined if HIV-1 infection causes
increased processing of cathepsin to the functional forms.
Intracellular expression of cystatin B was also modulated by
HIV-1 infection in macrophages. With time in culture, the
expression of cystatin B increased in HIV-1 infected macrophages
and reached significantly higher levels than those seen in
uninfected cells. These results are consistent with previous
observations made in our laboratory, where Luciano-Montalvo
et al. [49] found increased cystatin B expression in MDM infected
with another macrophage-tropic HIV-1 strain (HIV-1Bal) after 12
dpi. However, increased cystatin B protein with no differences in
mRNA levels may reflect intracellular retention of this enzyme, as
demonstrated by a tendency to achieve lower levels of secretion in
HIV-infected cultures as compared to uninfected controls.
Cysteine proteases, including cathepsin B, are ubiquitous host
proteins involved mainly in non-selective intracellular protein
degradation in lysosomes [50]. Outside lysosomes, cathepsins are
tightly regulated by cystatins [50]. [51]. Until recently, cathepsins
were thought to be completely inactive at neutral pH, but several
groups have provided evidence associating cytoplasmic and
secreted cathepsin B with inflammation [52,53,54] and apoptosis
[19,21,55,56,57,58]. It is well known that HIV infection triggers
TNF- a and IL-1 inflammatory pathways [28] and that action is
associated with increased oxidative stress [21,50] and antioxidant
dysfunction [45] during HAND. Oxidative stress [59] and TNF-
a [60] can promote the release of cathepsin B from lysosomes. Our
results indicate a significant decrease in the interactions between
cathepsin B and the lysosome in HIV-1 infected MDM, suggesting
that HIV-1 triggers the release of cathepsin B from this organelle.
Similar results found by others associated the translocation of
cathepsin B from the lysosome to the cytosol with apoptosis in
other inflammatory diseases [61,62]. Consistent with a possible
link between oxidative stress and cathepsin B activity, recent
studies by several groups showed that antioxidants can prevent
Figure 6. Cathepsin B does not interact with cystatin B in HIV-infected MDM. In situ PLA (Duolink) assay showed interaction between
cathepsin B and cystatin B in uninfected (A, B and C; top panels) and decreased interactions in HIV infected MDM (D, E and F; bottom panels).
Expression of cathepsin B (red) and cystatin B (green) was confirmed by immunofluorescence in uninfected (G and H; right top panels) and HIV-
infected MDM (I and J; right bottom panels). This is a representative figure from 3 experiments performed.
doi:10.1371/journal.pone.0036571.g006
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For example, treatment with proanthoyanidin antioxidants, which
are members of the flavonoid family, resulted in a decrease in
oxidative stress and levels of lysosomal enzymes, including
cathepsin B [63]. Furthermore, addition of gallic or caffeic acid
prevented lysosomal damage and reduced levels of cathepsin B
activity, respectively [63,64]. These studies confirm that cathepsin
B can be released from lysosomes in response to oxidative stress,
and suggest the potential use of antioxidants as therapeutic agents
to prevent cathepsin B release and neurotoxicity.
Another potential mechanism whereby HIV might affect
cathepsin activity is through increased lysosomal permeability.
The HIV protein Nef has been shown to directly promote
lysosomal membrane permeabilization, with resulting efflux of
cathepsins into the cytosol [65]. An alternative or additional
mechanism would involve generalized activation of proteasomal
proteins, and there is evidence that another viral protein, Vif,
activates the proteasome pathway to target antiviral proteins for
degradation as a mechanism to enhance viral infectivity [66]. As
cathepsins are the main proteins involved in proteasomal
degradation, increased activity of this pathway triggered by Vif
might promote the synthesis of cathepsin B, which could result in
its over-expression and accumulation. Finally, it has been shown
that HIV infection can induce the translocation of cystatin B from
the cytosol to the plasma membrane [67]. This sequestration of
cystatin B to the membrane limits the availability of this protein in
the cytoplasm to inhibit released cathepsin B. Thus, multiple
alterations in macrophage physiology induced by HIV-1 infection
may act together to affect cathepsin B availability and activity.
When levels of cathepsin B released from lysosomes exceed
those of available cystatins, the protease inhibitor ratio is
disrupted, and free active cathepsin B can indiscriminately
degrade essential proteins and/or be secreted from the cell [50].
In this study, we showed that MDM released active cathepsin B
and that HIV-1 infection increased levels of active cathepsin B
over time of infection. Other groups have associated increased
cathepsin B activity with infections by several other viruses, such as
human Papilloma virus [68], Influenza A virus [69], Adeno-
associated virus [70], and Norovirus [71]. In terms of cathepsin B’s
mechanism of action after viral infection, our observations confirm
the results of Furman’s group, and extend them by showing that
not only does cathepsin B increase after viral infection, but the
activity of secreted cathepsin B is also modulated.
Figure 7. Cathepsin B does not interacts with cystatin C in HIV-infected MDM. In situ PLA (Duolink) assay shows interaction between
cathepsin B and cystatin C in uninfected cells (A, B and C; top panels) and decreased interactions in HIV infected MDM (D, E and F; bottom panels).
Expression of cathepsin B (red) and cystatin C (green) was confirmed by immunofluorescence in uninfected (G and H; right top panels) and HIV-
infected MDM (I and J; right bottom panels). This is a representative figure from 3 experiments performed.
doi:10.1371/journal.pone.0036571.g007
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modulated by cystatins. Cystatins are the endogenous inhibitors
of cysteine proteases, with cystatin B and cystatin C being the two
major inhibitors of cathepsin B. It was believed that cystatin B
acted primarily in the intracellular compartment, while cystatin C
was actively secreted to act on extracellular cathepsin B. However,
recent studies on HIV and other inflammatory diseases have
shown high levels of secreted cystatin B in response to either HIV
infection or inflammation [43,49]. Our results are consistent with
these findings, as we showed an increase in cystatin B secretion in
response to HIV-1 infection. Cystatin C has also been found by
others to respond to HIV and other viral infections [46,72].
However, we found no differences in the levels of secreted cystatin
C after HIV-1 infection. Changes in the expression of the two
principal inhibitors of cathepsin B, cystatin B and cystatin C, could
also represent a redundant mechanism to prevent damage caused
by free cathepsin B. However, an imbalance in the expression
levels of these two proteins could lead to an increase in free active
cathepsin B, which in turn could lead to neuronal dysfunction
during HAND. Our findings suggest that, although intracellular
cystatin B expression increases after HIV infection in MDM,
neither cystatin B or cystatin C inhibits cathepsin B activity.
Imbalance between cathepsin B and its inhibitors has been
reported in other inflammatory conditions such as pelvic in-
flammatory disease [54] and broncopulmonary dysplasia [73] In
both of those studies, cathepsin B was expressed at higher levels
than its inhibitors and thus contributed significantly to cell
damage. In this study, we analyzed the ratio of secreted cathepsin
B to cystatin C in culture supernatants after HIV infection of
MDM. We found that cathepsin B levels were 2 to 4.5-fold higher
than cystatin C levels at all times, with a significant increase in the
cathepsin B/cystatin C ratio in HIV-infected cells. An imbalance
in the cathepsin B/cystatin C ratio implies the possibility of
a dysfunction in the interactions between the cystatins and
cathepsin B. Our data demonstrates that cathepsin B interacts
with its inhibitor in uninfected MDM, however in HIV-infected
MDM there is little or no interaction between cathepsin B and
either cystatin B or C. This indicates that HIV-1 not only
modulates the expression of cathepsin B but it also inhibits
protease: inhibitor interactions, promoting in consequence an
increased active cathepsin B secretion. This dysfunction might
allow the release of active cathepsin B into the extracellular space,
which could then promote neuronal apoptosis.
An important goal of our study was to determine if cathepsin B
could have a potential role in HIV neuropathogenesis by
analyzing its intracellular and extracellular expression and activity
in MDM relative to HIV-1 infection. We studied neuronal
apoptosis using the neuroblastoma cell line SK-N-SK, which has
been used to study pathways of neuronal apoptosis in several
neurodegenerative diseases, including HIV-1 associated neurode-
generation [74,75,76]. Although we did not induce the cells to
differentiate with retinoic acid, nonetheless the cells expressed
Figure 8. Expression of cathepsin B and cystatin B in the hippocampus of post-mortem brain tissues. Hippocampal tissue from HIV-
seronegative (A, F and K) and HIV-seropositive (B-E, G-J and L-O) patients were stained with mouse anti-human cathepsin B followed by Alexa 488
conjugate goat anti-mouse (green), or mouse anti-human cystatin B followed by Alexa 488 conjugate goat anti-mouse (green), and rabbit anti-
human Iba-1 followed by Alexa 546 goat anti-rabbit (red), and nuclear staining by DAPI (blue). Hippocampus samples from the same patients stained
only with secondary antibodies and DAPI were used as negative controls illustrated in K-O. For each color, detector gains were maintained standard
in every caption taken with the Pascal software in a Zeiss LSM 5 confocal laser-scanning microscope using a 636magnification.
doi:10.1371/journal.pone.0036571.g008
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neurons (Figure S2). Our results provide evidence for the first time
of a role for MDM-secreted cathepsin B in the neuronal apoptosis
induced by HIV-1 infection. Specifically, we showed that by
inhibiting the high levels of cathepsin B secreted by HIV-infected
MDM, the neurotoxic activity of supernatants from these cells
could be abolished.
Cathepsin B has been associated with apoptosis, by both
caspase-dependent and independent pathways. It has been shown
that release of cathepsin B from lysosomes after TNF-a treatment
enhances mitochondrial release of cytochrome c and subsequent
caspase activation. In this model, deletion of cathepsin B gene
resulted in diminished apoptosis [19]. Several groups have shown
that the most likely route of cathepsin B-induced apoptosis is
through the cleavage of the Bcl-2 family pro-apoptotic member,
Bid [53,77,78]. However, Houseweart and collaborators reported
that cathepsin B promotes apoptosis in absence of the pro-
apoptotic protein Bid [79]. These observations suggest that
cathepsin B mediates apoptosis by multiple pathways and that in
the absence of Bid, other molecules can substitute for its pro-
apoptotic role. Thus, targeted inhibition of extracellular cathepsin
B could represent a useful addition to the therapeutic strategy for
HAND patients. Future studies will address if other cathepsins also
contribute to the neurotoxic activity of HIV-infected MDM, as has
been shown in other inflammatory diseases [80].
To further explore the possible role of cathepsin B and cystatin
B play in HAND, we did immunohistochemical analyses of post-
mortem tissue from three brain regions of uninfected and HIV-1
positive individuals: hippocampus, basal ganglia, and frontal lobe.
Cathepsin B and cystatin B proteins showed increased expression
in the hippocampus and basal ganglia of HIV-infected individuals
with MCMD and HAD compared to that seen in those brain
regions in the uninfected individual and an HIV-infected
individual with normal cognition. These results are consistent
with previous observations of increased lysosomal enzymes in post-
mortem brain tissue with HIV encephalitis [81], and provide
further support for our hypothesis that cathepsin B is involved in
HAND. Previous studies also demonstrated that perivascular
macrophages, microglia, and astrocytes have increased lysosomal
activity in the white matter during HAD [81]. Other studies
demonstrated that there is high activation of macrophages and
microglia in the basal ganglia and hippocampus of HIV-infected
people, despite suppression of HIV RNA in plasma due to
HAART therapy [82]. Therefore, these brain regions are
susceptible to an immune reaction during late stages of the
infection.
Increased cathepsin B was observed in the three HIV-infected
individuals with Alzheimer’s disease. Alzheimer’s disease is
characterized by abnormal accumulation of certain brain proteins,
including b-amyloid and tau [83]. Cathepsin B functions as a b-
Figure 9. Expression of cathepsin B and cystatin B in the basal ganglia of post-mortem brain tissues. Basal ganglia tissue from HIV-
seronegative (A, F and K) and HIV seropositive (B-E, G-J and L-O) patients were stained with mouse anti-human cathepsin B followed by Alexa 488
conjugate goat anti-mouse (green), or mouse anti-human cystatin B followed by Alexa 488 conjugate goat anti-mouse (green), and rabbit anti-
human Iba-1 followed by Alexa 546 goat anti-rabbit (red), and nuclear staining by DAPI (blue). Unstained tissues were used as controls as illustrated in
K to O. Magnification: 636.
doi:10.1371/journal.pone.0036571.g009
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cystatins B and C have the ability to directly bind to b-amyloid
peptides [85,86,87,88]. Skerget and coworkers found that cystatin
B prevents b-amyloid fibril formation in vitro [89]. In another study
in an Alzheimer’s disease mouse model, small-molecule inhibitors
of cathepsin B decreased b-amyloid levels and improved memory
performance [90]. These studies, together with our results, raise
the possibility that HIV-associated increases in cathepsin B levels
contribute to the development of Alzheimer’s disease in HIV-
infected individuals.
In conclusion, our results demonstrate that HIV infection
dysregulates cathepsin B in macrophages, at both the mRNA and
protein levels, leading to increased secretion of bioactive cathepsin
B that contributes to neuronal apoptosis. In addition, our data
shows a failure of cystatins B and C to prevent the secretion and
activity of cathepsin B in the extracellular environment, probably
due to dysfunction in their interactions with cathepsin B. Future
experiments will be aimed at determining what protein modifica-
tions in cystatin B prevent this interaction. In addition, further
study of cathepsin B expression in the brains of HIV-infected
individuals with and without cognitive impairment will be
necessary to confirm the role of cathepsin B in HAND.
Supporting Information
Figure S1 Intracellular expression of cathepsin B and
its inhibitors after HIV infection in macrophages. HIV
replication was measured in the cell supernatants by p24 viral
antigen ELISA (A). In vitro HIV-infected macrophages from 4
different donors (solid circles) showed an increase in HIV
replication at 12 dpi (p,0.001; A). Differences in expression of
cathepsin B, cystatin B, and cystatin C at 6, 9 and 12 dpi; panels B,
C and D and E) were determined by Western blot analysis.
Aliquots of 30 mg of total protein were loaded per line blotted and
probed with antibodies against cathepsin B, cystatin B, cystatin C
(B). The density of the bands was normalized (C, D and E) against
that of b-tubulin (A bottom panel). Normalized data are presented
for cathepsin B (open bars), cystatin B (grey bars), and cystatin C
(solid bars). Levels of cathepsin B in HIV-infected and uninfected
cells remained unchanged through infection (C, D and E).
Cystatin B levels were significantly higher (*p,0.05) in HIV-
infected MDM compared with uninfected controls at 12 dpi
(p#0.05; E). No changes were seen in the levels of cystatin C
during HIV infection (C-E).
(TIF)
Figure S2 Neurofilament staining of SK-N-SH cells in
culture. SK-N-SH neuroblastoma cells were cultivated in slide
chambers, and fixed with a methanol/acetone solution. Primary
antibody MAB 5266 MS x Neurofilament 200 kD (Chemicon
Temecula, CA) was used to stain heavy neurofilaments at 1:1000
dilution followed by 1 hr incubation at room temperature. A
secondary antibody (Alexa 488 Goat Anti-Mouse IgG) was added
at 1:2000 dilution and incubated for 1 hour at room temperature.
DAPI was used for nuclear staining (blue). Panels A to E represent
different fields to demonstrate that SK-N-SH show evidence of
maturation by positive neurofilament staining. Confocal images
were obtained on a Zeiss confocal microscope Axiovert 200 M
with a LSM 510 with 636 magnification (panels A and B) with
a 2.5 zoom amplification (panels C to E).
(TIF)
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